Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06588868
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma an Observational Retrospective Multicenter Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FIL_CTCL
Brief Summary:
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting
Detailed Description:
The treatment of Mycosis Fungoides MFSézary Syndrome SS is based on a multimodal approach through the involvement of different specialists including hematologists dermatologists and radiation therapists The approach to the treatment combines different skin directed and systemic therapies such as chemotherapies immunomodulating agents immunotherapies
Although there are several well recognized therapies for the treatment of MFSS curative therapies are still needed In this scenario effective treatments that provide long term responses and disease control are still lacking Also International guidelines EORTC 2017 ESMO 2018 BAD2018 NCCN report treatment options for the different stages without recommendations of any order due to lack of evidence from clinical trials
This study is designed to analyze the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting
Although there are several well recognized therapies for the treatment of MFSS curative therapies are still needed In this scenario effective treatments that provide long term responses and disease control are still lacking Also International guidelines EORTC 2017 ESMO 2018 BAD2018 NCCN report treatment options for the different stages without recommendations of any order due to lack of evidence from clinical trials
This study is designed to analyze the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None